Semaglutide vs Surgery: Same Stiffness Drop, Less Fat Loss
A prospective observational cohort published in the Journal of Clinical Endocrinology and Metabolism on 27 August 2026 followed 92 adults with obesity for 72 weeks and split them three ways: lifestyle therapy alone, lifestyle plus semaglutide, and lifestyle plus laparoscopic sleeve gastrectomy.
On liver fat, surgery won by a wide margin. On liver stiffness, the relative reduction was not significantly different between semaglutide and surgery.
Bariatric surgery removes far more weight than a GLP-1 receptor agonist does. Two measurements from the same instrument, in the same patients, and only one of them tracked that difference.
A framing note. Semaglutide is an approved medicine, this is a study of patients, and semaglutide is not in the Peptra Labs catalogue. Nothing here is guidance about human use, about weight loss, or about surgery.
How the semaglutide comparison was set up
The work comes from the University of Lübeck, single centre, prospective and observational rather than randomised.
Ninety-two adults with obesity were analysed over 72 weeks in three groups: lifestyle-based multimodal therapy alone (30 patients), lifestyle plus semaglutide (30), and lifestyle plus laparoscopic sleeve gastrectomy (32). Every patient had hepatic steatosis at baseline.
The measurements came from FibroScan, which produces two separate readings from the same probe placement. The controlled attenuation parameter, CAP, estimates how much fat is in the liver. Liver stiffness measurement, LSM, estimates how fibrotic it is. The authors also calculated FIB-4 and FibroScan-AST scores.
Two readouts from one device matters here, because it removes a common objection. When two endpoints diverge across different instruments you can blame the instruments. When they diverge on the same machine, in the same session, the divergence is in the biology or in the disease.
What separated and what did not
| Measure over 72 weeks | Lifestyle | Semaglutide | Surgery |
|---|---|---|---|
| Liver fat, CAP change in dB/m | -17.9 | -46.0 | -83.7 |
| Liver stiffness, LSM change in kPa | -0.8 | -2.8 | -4.9 |
The CAP column is a clean dose-response of intervention intensity. Lifestyle moves it a little, semaglutide moves it two and a half times more, surgery moves it nearly twice again.
The stiffness column looks similar in absolute terms, and this is where the paper turns. Baseline stiffness differed between the groups, so absolute change is not the right comparison. The authors report the relative reduction instead, and there was no significant difference between semaglutide and surgery, with a p value of 0.428.
FibroScan-AST scores decreased significantly over time in all three groups.
Why the split matters
Liver fat and liver stiffness are not the same disease process, and treating them as one number is the most common error in this field.
Steatosis is fat accumulation. It responds quickly to energy balance and it can move a long way in weeks. Fibrosis is deposited collagen, it accumulates over years, and it is the thing that predicts cirrhosis and death. Everything anyone actually cares about in liver disease sits on the fibrosis side.
So a result where a much larger intervention wins decisively on the fast, reversible measure and ties on the slow, consequential one is not a small footnote. It suggests that whatever improves stiffness in these patients is not simply proportional to how much fat comes off or how much weight is lost.
The caution is that LSM is a proxy. Transient elastography estimates stiffness rather than measuring collagen, and it is affected by inflammation, congestion and recent food intake. A tie on a proxy is weaker evidence than a tie on histology.
The fifth line in the same direction
This is now the fifth paper this month pointing at the same gap, and we have written about all of them.
A prespecified analysis of SELECT found the inflammatory marker fell before the weight did. In a matched cohort where hard liver outcomes came out level, tirzepatide dropped more BMI than semaglutide and produced identical cirrhosis, decompensation and hepatocellular carcinoma rates. A colitis cohort found remission with no association to weight loss. Yesterday we covered a population with a BMI under 27, where a heart failure signal appeared in people with almost nothing to lose.
Now surgery and a drug, separated by roughly double on liver fat, tied on stiffness.
Five studies, four organs, one shape. None of them measures a mechanism, and that is exactly the problem. Every one of these is an outcome or a marker, and the sentence that would settle the question, a direct measurement in human tissue, has not appeared in anything we can read.
It also sits awkwardly against a 52-week MASH biopsy trial we covered earlier this month, where a combination arm beat monotherapy on every histological number and still missed its primary endpoints. Histology moved without the endpoint. Here stiffness moved without the fat difference. The intermediate measure and the consequential one keep failing to line up in both directions.
Three limits worth naming
Ninety-two patients, one centre, not randomised. Who ends up in a surgery arm rather than a drug arm is not a random assignment, and the two populations differ in ways a single-centre observational design cannot fully account for.
Seventy-two weeks is short for fibrosis. Collagen turnover is slow. A tie at seventeen months does not mean a tie at five years, in either direction.
Baseline stiffness differed between groups, which is why the authors moved to relative reduction. That is the correct handling, and it also means the headline comparison rests on a ratio rather than on directly comparable starting points.
What this means for the catalogue
Neither compound in this study is what we supply, and the useful content for a laboratory is the measurement lesson rather than the clinical one.
Two readouts from one probe, diverging, is the cheapest available demonstration that a treatment can move a marker without moving the thing the marker is supposed to stand for. That distinction runs through the whole research peptide field, where almost every published claim rests on an intermediate measure.
Retatrutide is the compound where this question will get asked next, because glucagon receptor agonism has direct hepatic effects that neither intervention here possesses. It has no liver outcome trial completed, which means for now the honest answer about the triple agonist and the liver is that nobody knows.
For laboratories, our European research buyer guide covers procurement and documentation, everything is supplied on a research use only basis, and our ranking of the most-studied research peptides tracks the published record for each compound.
References
- Lünswilken P, Worobiec K, Braun LS, et al. Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD. Journal of Clinical Endocrinology and Metabolism, 27 August 2026. doi 10.1210/clinem/dgag350
- Banerjee M, Roy A, Sharma VM, Das A. Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes. Obesity (Silver Spring), 19 August 2026
- Chen SC, Huang YN, Li PY, et al. Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation. Diabetes, Obesity and Metabolism, 25 August 2026
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
